JP2024505212A5 - - Google Patents

Info

Publication number
JP2024505212A5
JP2024505212A5 JP2023545813A JP2023545813A JP2024505212A5 JP 2024505212 A5 JP2024505212 A5 JP 2024505212A5 JP 2023545813 A JP2023545813 A JP 2023545813A JP 2023545813 A JP2023545813 A JP 2023545813A JP 2024505212 A5 JP2024505212 A5 JP 2024505212A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
cbd
sleep
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023545813A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024505212A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2022/050781 external-priority patent/WO2022162621A1/en
Publication of JP2024505212A publication Critical patent/JP2024505212A/ja
Publication of JP2024505212A5 publication Critical patent/JP2024505212A5/ja
Pending legal-status Critical Current

Links

JP2023545813A 2021-01-28 2022-01-28 Ｃｂｄを用いた睡眠時無呼吸の処置 Pending JP2024505212A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163142835P 2021-01-28 2021-01-28
US63/142,835 2021-01-28
PCT/IB2022/050781 WO2022162621A1 (en) 2021-01-28 2022-01-28 Treatment of sleep apnea with cbd

Publications (2)

Publication Number Publication Date
JP2024505212A JP2024505212A (ja) 2024-02-05
JP2024505212A5 true JP2024505212A5 (https=) 2025-01-28

Family

ID=80222209

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023545813A Pending JP2024505212A (ja) 2021-01-28 2022-01-28 Ｃｂｄを用いた睡眠時無呼吸の処置

Country Status (11)

Country Link
US (1) US20240307418A1 (https=)
EP (1) EP4284349A1 (https=)
JP (1) JP2024505212A (https=)
KR (1) KR20230137404A (https=)
CN (1) CN116829135A (https=)
AU (1) AU2022213009A1 (https=)
CA (1) CA3206508A1 (https=)
IL (1) IL304827A (https=)
JO (1) JOP20230169A1 (https=)
MX (1) MX2023008876A (https=)
WO (1) WO2022162621A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2627344A (en) * 2022-12-16 2024-08-21 Kingdom Therapeutics Ltd Cannabinoid based therapy

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8449908B2 (en) 2000-12-22 2013-05-28 Alltranz, Llc Transdermal delivery of cannabidiol
CA2760460C (en) 2009-04-28 2019-04-02 Alltranz Inc. Transdermal formulations of cannabidiol comprising a penetration enhancer and methods of using the same
BR112019026877A2 (pt) * 2017-06-19 2020-06-30 Zelda Therapeutics Operations Pty Ltd composições para distúrbios do sono e tratamentos do mesmo
IL278548B2 (en) * 2018-05-11 2025-07-01 Rhodes Tech Inc Pharmaceutical preparations containing dronabinol and sprays containing the same pharmaceutical preparations
WO2019224824A1 (en) * 2018-05-24 2019-11-28 To Pharmaceuticals Llc Cannabis-based compositions for the treatment of autistic spectrum disorders
BR112022004175A2 (pt) * 2019-09-17 2022-05-31 Zynerba Pharmaceuticals Inc Tratamento de encefalopatia de syngap1

Similar Documents

Publication Publication Date Title
Clark et al. Sleep apnea: treatment with protriptyline
Andrade et al. The role of physical exercise in obstructive sleep apnea
Schütz et al. New frontiers in pharmacologic obstructive sleep apnea treatment: a narrative review
Stepnowsky Jr et al. Nasal CPAP treatment for obstructive sleep apnea: developing a new perspective on dosing strategies and compliance
US20150272934A1 (en) Use of cse inhibitors for the treatment of cutaneous injuries or conditions and sleep-related breathing disorders
RU2010121827A (ru) Композиции для лечения болезни паркинсона
PT705099E (pt) Utilizacao do modafinil para o tratamento da apneia do sono e problemas respiratorios de origem central
JP2025084754A (ja) 睡眠時無呼吸を治療するための方法および組成物
JP4896334B2 (ja) 睡眠時呼吸障害を治療及び診断する方法並びにその方法を実施する手段
Lehmann et al. Mitigation of electroencephalographic and cardiovascular responses to castration in Bos indicus bulls following the administration of either lidocaine or meloxicam
JP2024505212A5 (https=)
KR101187461B1 (ko) 각성을 향상시키는 방법
Wojda et al. Mandibular advancement devices in obstructive sleep apnea patients intolerant to continuous positive airway pressure treatment
US5502067A (en) Treating apneahypopnea/snoring in humans
Aishah et al. P001 Safety, tolerability, and efficacy of 1 month of atomoxetine plus oxybutynin in obstructive sleep apnoea
US20240139200A1 (en) Combination of reboxetine and a muscarinic receptor antagonist (mra) for use in treating sleep apnea
CN116712420B (zh) 一种花椒酰胺在制备治疗多发性硬化症的药物中的应用
Aishah et al. P002 Targeted non-CPAP combination therapy resolves obstructive sleep apnoea
CN115154448B (zh) 一种治疗不宁腿综合征的药物及其制备方法和应用
Wojda et al. in Obstructive Sleep Apnea Patients Intolerant to Continuous Positive Airway
CN107412234A (zh) 一叶萩碱的药物用途
Amaranayake et al. P003 The impact of forced wake from overnight polysomnography on multiple sleep latency test results
Hu et al. Low dose esketamine for gastrointestinal endoscopy: a double-blinded, randomized controlled trial.
Lockhart (834): Topical sterile lidocaine patch to reduce postoperative pain and decrease need for oral analgesics after inguinal herniorrhaphy
TW202310855A (zh) 使用一氧化二氮或任何吸入性麻醉劑治療covid-19及其他病毒感染、細菌感染、損傷、急性呼吸窘迫症候群或導致p物質水平急性升高引起細胞激素系統之病理性活化之病症